Biogaia

Biogaia Debt/EBITDA

The Total Debt to EBITDA Ratio of Biogaia (BIOG B.ST) as of Nov 21, 2026 is 0.02. In the previous year, Total Debt to EBITDA Ratio was 0.02 — a change of 1.36% (higher).

Debt/EBITDA

0.02

YoY

1.36%

Last updated:

Total Debt to EBITDA Ratio of Biogaia is 2025 0.02 . Total Debt to EBITDA Ratio of Biogaia was 2024 0.02 . It decreases by 1.36% higher compared to the previous year.

The Biogaia Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-0.09 SEK
Jan 1, 2019
0.11 SEK
Jan 1, 2020
0.13 SEK
Jan 1, 2021
0.04 SEK
Jan 1, 2022
0.04 SEK
Jan 1, 2023
0.02 SEK
Jan 1, 2024
0.02 SEK
Jan 1, 2025
0.02 SEK
The Biogaia Debt/EBITDA history
YEARDebt/EBITDAYoY
0.02+1.36%
0.02-15.73%
0.02-55.16%
0.04+8.39%
0.04-68.49%
0.13+20.43%
0.11-219.35%
-0.09-42.80%
-0.16+43.69%
-0.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biogaia Stock analysis

What does Biogaia do? BioGaia AB generates revenue through its probiotic product segments, primarily featuring Limosilactobacillus reuteri strains. The Paediatrics segment sells drops, gut health tablets, oral rehydration solutions, and cultures for licensee products. The Adult Health segment offers gut health tablets, oral health lozenges, and cultures integrated into dairy products by licensees. The Other segment includes royalties from development projects and revenue from CapAble's packaging solutions. Products are marketed globally to consumers seeking health benefits from probiotics, with licensees distributing branded items under agreements. The company targets health-conscious consumers through direct sales and licensed partnerships. Paediatrics products focus on infant and child health, while Adult Health products address digestive and oral wellness. CapAble, a subsidiary, contributes through packaging solutions, and royalties from development projects provide additional income streams. All segments operate under BioGaia's brand, leveraging documented health benefits of their probiotic strains. Biogaia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biogaia stock

Total Debt to EBITDA Ratio of Biogaia is 0.02 in 2025.

Total Debt to EBITDA Ratio of Biogaia changed from 0.02 to 0.02, representing a 1.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Biogaia since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Biogaia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biogaia

All Key Metrics — Biogaia